Accustem Sciences Inc. (ACUT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00444A1016
Accustem Sciences Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Operating income | -1.51 m USD | -1.76 m USD |
| EBIT | -1.51 m USD | -1.76 m USD |
| Net income | -1.51 m USD | -1.76 m USD |
| Diluted EPS – continuing operations | -0.13 USD | -0.12 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Accustem Sciences Inc.
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
More stocks
- MUSTANG BIO, INC. (MBIO)
- Nexalin Technology, Inc. (NXL)
- Sunshine Biopharma Inc. (SBFM)
- NEXGEL, INC. (NXGL)
- Circle Energy, Inc./NV (CRCE)
- ALTEX INDUSTRIES INC (ALTX)
- KUSTOM ENTERTAINMENT, INC. (KUST)
- OCULUS INC. (OVTZ)
- OMNIQ Corp. (OMQS)
- BioRestorative Therapies, Inc. (BRTX)
- HCW Biologics Inc. (HCWB)
- Polar Power, Inc. (POLA)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.